Top Markets
Coin of the day
NeuroSense Therapeutics Ltd. NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd.

NRSN
Rangering i aksjer #31257
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical... NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Aksjekurs
$0.39
Markedsverdi
$13.79M
Endring (1 dag)
-13.53%
Endring (1 år)
-68.80%
Land
IL
Handel NeuroSense Therapeutics Ltd. (NRSN)

Kategori

P/B-forhold for NeuroSense Therapeutics Ltd. (NRSN)
P/B-forhold per 2026 TTM: 0
Ifølge NeuroSense Therapeutics Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for NeuroSense Therapeutics Ltd. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
3.4612 -
BE